Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Luciana
L
Teofili
Fiorina
F
Giona
Maurizio
M
Martini
Lorenza
L
Torti
Tonia
T
Cenci
Robin
R
Foà
Giuseppe
G
Leone
Luigi M
LM
Larocca
D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use; D009154:Mutation; D055728:Primary Myelofibrosis / Q000139:chemically induced; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011961:Receptors, Fc / Q000627:therapeutic use; D053628:Receptors, Thrombopoietin / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000097:blood / Q000188:drug therapy; D013922:Thrombocytosis / Q000235:genetics* / Q000378:metabolism; D013926:Thrombopoietin / Q000009:adverse effects / Q000627:therapeutic use; D015533:Transcriptional Activation / Q000187:drug effects
D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag